Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Depreciation & Amortization (CF) (2016 - 2025)

Utah Medical Products (UTMD) has 16 years of Depreciation & Amortization (CF) data on record, last reported at $209000.0 in Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) rose 2.96% year-over-year to $209000.0; the TTM value through Sep 2025 reached $814000.0, up 18.31%, while the annual FY2024 figure was $730000.0, 17.17% up from the prior year.
  • Depreciation & Amortization (CF) reached $209000.0 in Q3 2025 per UTMD's latest filing, up from $205000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $209000.0 in Q3 2025 and bottomed at $149000.0 in Q1 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $169210.5, with a median of $158000.0 recorded in 2021.
  • Peak YoY movement for Depreciation & Amortization (CF): decreased 8.59% in 2022, then skyrocketed 30.97% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $153000.0 in 2021, then grew by 3.27% to $158000.0 in 2022, then changed by 0.0% to $158000.0 in 2023, then grew by 26.58% to $200000.0 in 2024, then rose by 4.5% to $209000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $209000.0 in Q3 2025, $205000.0 in Q2 2025, and $200000.0 in Q1 2025.